<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000661</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 124</org_study_id>
    <nct_id>NCT00000661</nct_id>
  </id_info>
  <brief_title>The Pharmacokinetics of Zidovudine and Oxazepam Alone and in Combination in the HIV-Infected Patient</brief_title>
  <official_title>The Pharmacokinetics of Zidovudine and Oxazepam Alone and in Combination in the HIV-Infected Patient</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To determine if a pharmacokinetic (blood level) interaction exists between zidovudine (AZT)&#xD;
      and oxazepam in the HIV-infected patient. Benzodiazepines (such as oxazepam) are among the&#xD;
      most frequently prescribed class of drugs and are commonly used therapeutically for patients&#xD;
      with chronic disease. This study is important because of the potential for toxicity resulting&#xD;
      from a reaction between AZT and benzodiazepines and the likelihood of frequent use of the&#xD;
      combination of these drugs in patients with HIV infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Benzodiazepines (such as oxazepam) are among the most frequently prescribed class of drugs&#xD;
      and are commonly used therapeutically for patients with chronic disease. This study is&#xD;
      important because of the potential for toxicity resulting from a reaction between AZT and&#xD;
      benzodiazepines and the likelihood of frequent use of the combination of these drugs in&#xD;
      patients with HIV infection.&#xD;
&#xD;
      Patients are studied to determine oral and intravenous AZT and single oral dose oxazepam&#xD;
      pharmacokinetics. Patients then take AZT and oxazepam together to determine if interactions&#xD;
      between the drugs occur.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>8</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxazepam</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Required:&#xD;
&#xD;
          -  Stable prescribed dosage of zidovudine (AZT), = or &gt; 500 mg/day.&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Prophylaxis for Pneumocystis carinii pneumonia (PCP) with aerosolized pentamidine.&#xD;
&#xD;
          -  Erythropoietin.&#xD;
&#xD;
        Patients must be:&#xD;
&#xD;
          -  HIV positive by ELISA and Western blot.&#xD;
&#xD;
          -  Currently taking a stable prescribed dosage of 500 mg/day of zidovudine (AZT).&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  Allergy to benzodiazepines or a previously documented intolerance to zidovudine (AZT)&#xD;
             therapy of = or &lt; 600 mg/day.&#xD;
&#xD;
          -  Significant underlying medical condition that could impair continuous participation in&#xD;
             study.&#xD;
&#xD;
          -  Malabsorption syndrome (3 or more loose stools a day for at least 4 weeks associated&#xD;
             with an unintentional weight loss of at least 10 percent of body weight).&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Oral contraceptives.&#xD;
&#xD;
          -  Cytotoxic chemotherapy.&#xD;
&#xD;
          -  Ganciclovir.&#xD;
&#xD;
          -  Flucytosine.&#xD;
&#xD;
          -  Probenecid.&#xD;
&#xD;
          -  Opiates.&#xD;
&#xD;
          -  Valproic acid.&#xD;
&#xD;
          -  Sulfa drugs.&#xD;
&#xD;
          -  Sucralfate.&#xD;
&#xD;
          -  Dapsone.&#xD;
&#xD;
          -  Rifampin.&#xD;
&#xD;
          -  Antacids within 2 hours of zidovudine (AZT) dose.&#xD;
&#xD;
          -  Isoniazid.&#xD;
&#xD;
          -  Ketoconazole.&#xD;
&#xD;
          -  Pyrimethamine.&#xD;
&#xD;
          -  Clindamycin.&#xD;
&#xD;
          -  Aspirin.&#xD;
&#xD;
          -  Ibuprofen.&#xD;
&#xD;
          -  Investigational drugs not specifically allowed.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Allergy to benzodiazepines or a previously documented intolerance to zidovudine (AZT)&#xD;
             therapy of = or &lt; 600 mg/day.&#xD;
&#xD;
          -  Significant underlying medical condition that could impair continuous participation in&#xD;
             study.&#xD;
&#xD;
          -  Unable to take oral medication reliably.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 30 days of study entry:&#xD;
&#xD;
          -  Antiretroviral agents other than zidovudine (AZT).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Israelski D</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Blaschke T</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Palo Alto Veterans Adm Med Ctr / Stanford Univ</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Mole LA, Israelski DM, Bubp JL, O'Hanley P, Merigan T, Blaschke T. The pharmacokinetics (PK) of zidovudine (ZDV) and oxazepam (OXA) alone and in combination in the HIV-infected patient (ACTG 124). Int Conf AIDS. 1992 Jul 19-24;8(2):B186 (abstract no PoB 3595)</citation>
  </reference>
  <reference>
    <citation>Mole L, Israelski D, Bubp J, O'Hanley P, Merigan T, Blaschke T. Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient. J Acquir Immune Defic Syndr (1988). 1993 Jan;6(1):56-60.</citation>
    <PMID>8417175</PMID>
  </reference>
  <verification_date>December 1994</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>August 1, 2008</last_update_submitted>
  <last_update_submitted_qc>August 1, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2008</last_update_posted>
  <keyword>Oxazepam</keyword>
  <keyword>Drug Evaluation</keyword>
  <keyword>Drug Interactions</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Oxazepam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

